Ongoing treatment(s)-Bone marrow transplant - Page 3 of 5 Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Bone marrow transplant Posts on Medivizor

Searching for patients with lymphoma or leukemia to test T-cell therapy after stem cell transplantation

Posted by on May 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 trial is evaluating how well CD8+ memory T-cell therapy works in patients with leukemia or lymphoma after a stem cell transplant (SCT). The main outcome to be measured will be the number of patients who have full chimerism (donor cells work completely and only donor cells can be identified after transplant) after therapy. This...

Read More

What role does the graft-versus-leukemia effect have on survival in acute lymphoblastic leukemia?

Posted by on Mar 20, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of graft-versus-leukemia effect on survival in patients with acute lymphoblastic leukemia. This study concluded that graft-versus-leukemia effect was beneficial in certain subsets of these patients. Some background Allogeneic hematopoietic stem cell transplant (allo-HSCT) is a potentially...

Read More

Evaluating BEAM conditioning for allogeneic stem cell transplantation in patients with relapsed or unresponsive lymphoma

Evaluating BEAM conditioning for allogeneic stem cell transplantation in patients with relapsed or unresponsive lymphoma

Posted by on Jan 17, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...

Read More

Evaluating the impact of early PET/CT scanning on survival in patients with lymphoma after stem cell transplant

Evaluating the impact of early PET/CT scanning on survival in patients with lymphoma after stem cell transplant

Posted by on Dec 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...

Read More

Evaluating the impact of older age on patient outcomes after allogenic stem cell transplantation for NHL

Evaluating the impact of older age on patient outcomes after allogenic stem cell transplantation for NHL

Posted by on Oct 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the impact of older age on the outcomes of patients with non-Hodgkin’s lymphoma (NHL) who underwent allogeneic stem cell transplantation (alloSCT). This study concluded that alloSCT in patients older than 65 was associated with higher risks. Some background More than 60% of patients with NHL are older than...

Read More

Evaluating BendaEAM chemotherapy before stem cell transplantation for relapsed lymphoma

Evaluating BendaEAM chemotherapy before stem cell transplantation for relapsed lymphoma

Posted by on Sep 28, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of the BendaEAM (bendamustine, etoposide, cytarabine, melphalan) in patients with lymphoma undergoing autologous stem cell transplantation (auto-SCT). This study concluded that BendaEAM is a feasible option for these patients, with minimal side effects. Some background High-dose...

Read More

Evaluating the risk of developing acute myeloid leukemia or myelodysplastic syndrome after a stem cell transplant

Evaluating the risk of developing acute myeloid leukemia or myelodysplastic syndrome after a stem cell transplant

Posted by on Sep 4, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) development in patients with lymphoma and myeloma after an autologous stem cell transplant (autoSCT). This study concluded that this risk is quite high after autoSCT in these patients. Some background AML and MDS are known long-term...

Read More

Evaluating the outcomes after second-line therapy for relapsed or refractory PMBCL

Evaluating the outcomes after second-line therapy for relapsed or refractory PMBCL

Posted by on Aug 17, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the outcomes of pretreated patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) primary mediastinal large B-cell lymphoma (PMBCL) after second-line therapy and stem cell transplant (SCT). The study concluded that this treatment strategy was effective in most patients. Some...

Read More

Overall survival and relapse rate in adults with AML who have received a stem cell transplant from a donor

Overall survival and relapse rate in adults with AML who have received a stem cell transplant from a donor

Posted by on Aug 1, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to identify the outcomes and prognostic factors following a stem cell transplant from a donor in adults with acute myeloid leukemia in their second complete remission (no sign of disease). The authors determined that this type of transplant was effective in these patients. Some background In adult patients with acute...

Read More

A comparison of two different types of transplant therapy to treat acute myeloid leukemia

A comparison of two different types of transplant therapy to treat acute myeloid leukemia

Posted by on Jul 15, 2018 in Leukemia | 0 comments

In a nutshell This study compared two different transplant therapies used to treat acute myeloid leukaemia (AML), unmanipulated haploidentical stem cell treatment (Haplo-SCT) and HLA-matched unrelated donor stem cell transplantation (MUD). The study found that both options are useful in treating AML but MUD may have increased risk of graft versus host...

Read More

Does risk level affect outcome of transplant treatments in acute myeloid leukemia?

Does risk level affect outcome of transplant treatments in acute myeloid leukemia?

Posted by on Jul 15, 2018 in Leukemia | 0 comments

In a nutshell This study compared two stem cell therapies called unmanipulated haploidentical and matched sibling donor transplant in the treatment of acute myeloid leukemia (AML).  The study concluded that matched sibling donor transplant was more effective in the treatment of AML. Some background AML is a cancer of the white blood cells in...

Read More